166 related articles for article (PubMed ID: 17305251)
1. Is there an optimum overall time for head and neck radiotherapy? A review, with new modelling.
Fowler JF
Clin Oncol (R Coll Radiol); 2007 Feb; 19(1):8-22. PubMed ID: 17305251
[TBL] [Abstract][Full Text] [Related]
2. Optimum overall times II: Extended modelling for head and neck radiotherapy.
Fowler JF
Clin Oncol (R Coll Radiol); 2008 Mar; 20(2):113-26. PubMed ID: 18155893
[TBL] [Abstract][Full Text] [Related]
3. Stochastic modelling of the role of cisplatin in altered fractionation schedules for head and neck cancer.
Marcu L; Bezak E
Phys Med; 2010 Oct; 26(4):177-83. PubMed ID: 20034829
[TBL] [Abstract][Full Text] [Related]
4. Monte Carlo radiotherapy simulations of accelerated repopulation and reoxygenation for hypoxic head and neck cancer.
Harriss-Phillips WM; Bezak E; Yeoh EK
Br J Radiol; 2011 Oct; 84(1006):903-18. PubMed ID: 21933980
[TBL] [Abstract][Full Text] [Related]
5. Randomized phase I/II trial of two variants of accelerated fractionated radiotherapy regimens for advanced head and neck cancer: results of RTOG 88-09.
Fu KK; Clery M; Ang KK; Byhardt RW; Maor MH; Beitler JJ
Int J Radiat Oncol Biol Phys; 1995 Jun; 32(3):589-97. PubMed ID: 7790243
[TBL] [Abstract][Full Text] [Related]
6. How worthwhile are short schedules in radiotherapy? A series of exploratory calculations.
Fowler JF
Radiother Oncol; 1990 Jun; 18(2):165-81. PubMed ID: 2367691
[TBL] [Abstract][Full Text] [Related]
7. Acute radiation reactions in oral and pharyngeal mucosa: tolerable levels in altered fractionation schedules.
Fowler JF; Harari PM; Leborgne F; Leborgne JH
Radiother Oncol; 2003 Nov; 69(2):161-8. PubMed ID: 14643953
[TBL] [Abstract][Full Text] [Related]
8. Altered fractionation outcomes for hypoxic head and neck cancer using the HYP-RT Monte Carlo model.
Harriss-Phillips WM; Bezak E; Yeoh EK
Br J Radiol; 2013 Apr; 86(1024):20120443. PubMed ID: 23392195
[TBL] [Abstract][Full Text] [Related]
9. Derivation of the optimum dose per fraction from the linear quadratic model.
Jones B; Tan LT; Dale RG
Br J Radiol; 1995 Aug; 68(812):894-902. PubMed ID: 7551788
[TBL] [Abstract][Full Text] [Related]
10. A randomised trial of accelerated and conventional radiotherapy for stage III and IV squamous carcinoma of the head and neck: a Trans-Tasman Radiation Oncology Group Study.
Poulsen MG; Denham JW; Peters LJ; Lamb DS; Spry NA; Hindley A; Krawitz H; Hamilton C; Keller J; Tripcony L; Walker Q
Radiother Oncol; 2001 Aug; 60(2):113-22. PubMed ID: 11439206
[TBL] [Abstract][Full Text] [Related]
11. Simultaneous integrated boost intensity-modulated radiotherapy for locally advanced head-and-neck squamous cell carcinomas: II--clinical results.
Lauve A; Morris M; Schmidt-Ullrich R; Wu Q; Mohan R; Abayomi O; Buck D; Holdford D; Dawson K; Dinardo L; Reiter E
Int J Radiat Oncol Biol Phys; 2004 Oct; 60(2):374-87. PubMed ID: 15380569
[TBL] [Abstract][Full Text] [Related]
12. Altered fractionation in the management of head and neck cancer.
Ang KK
Int J Radiat Biol; 1998 Apr; 73(4):395-9. PubMed ID: 9587077
[TBL] [Abstract][Full Text] [Related]
13. Smart (simultaneous modulated accelerated radiation therapy) boost: a new accelerated fractionation schedule for the treatment of head and neck cancer with intensity modulated radiotherapy.
Butler EB; Teh BS; Grant WH; Uhl BM; Kuppersmith RB; Chiu JK; Donovan DT; Woo SY
Int J Radiat Oncol Biol Phys; 1999 Aug; 45(1):21-32. PubMed ID: 10477002
[TBL] [Abstract][Full Text] [Related]
14. Improved results with accelerated hyperfractionated radiotherapy of advanced head and neck cancer.
Leborgne F; Zubizarreta E; Fowler J; Ortega B; Mezzera J; Deus JL; Leborgne JH
Int J Cancer; 2000 Apr; 90(2):80-91. PubMed ID: 10814958
[TBL] [Abstract][Full Text] [Related]
15. The potential for sparing of parotids and escalation of biologically effective dose with intensity-modulated radiation treatments of head and neck cancers: a treatment design study.
Wu Q; Manning M; Schmidt-Ullrich R; Mohan R
Int J Radiat Oncol Biol Phys; 2000 Jan; 46(1):195-205. PubMed ID: 10656393
[TBL] [Abstract][Full Text] [Related]
16. A Radiation Therapy Oncology Group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: first report of RTOG 9003.
Fu KK; Pajak TF; Trotti A; Jones CU; Spencer SA; Phillips TL; Garden AS; Ridge JA; Cooper JS; Ang KK
Int J Radiat Oncol Biol Phys; 2000 Aug; 48(1):7-16. PubMed ID: 10924966
[TBL] [Abstract][Full Text] [Related]
17. Investigation of various growth mechanisms of solid tumour growth within the linear-quadratic model for radiotherapy.
McAneney H; O'Rourke SF
Phys Med Biol; 2007 Feb; 52(4):1039-54. PubMed ID: 17264369
[TBL] [Abstract][Full Text] [Related]
18. Randomized phase I study of standard-fractionated or accelerated-hyperfractionated radiotherapy with concurrent cisplatin and vindesine for unresectable non-small cell lung cancer: a report of Japan Clinical Oncology Group Study (JCOG 9601).
Tsuchiya S; Ohe Y; Sugiura T; Fuwa N; Kitamoto Y; Mori K; Kobayashi H; Nakata K; Sawa T; Hirai K; Etoh T; Saka H; Saito A; Fukuda H; Ishizuka N; Saijo N;
Jpn J Clin Oncol; 2001 Oct; 31(10):488-94. PubMed ID: 11696618
[TBL] [Abstract][Full Text] [Related]
19. Modelling the optimal radiotherapy regime for the control of T2 laryngeal carcinoma using parameters derived from several datasets.
Roberts SA; Hendry JH; Slevin NJ
Int J Radiat Oncol Biol Phys; 1997 Dec; 39(5):1173-82. PubMed ID: 9392560
[TBL] [Abstract][Full Text] [Related]
20. Repair halftimes estimated from observations of treatment-related morbidity after CHART or conventional radiotherapy in head and neck cancer.
Bentzen SM; Saunders MI; Dische S
Radiother Oncol; 1999 Dec; 53(3):219-26. PubMed ID: 10660202
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
